short term borrowing from financial institutions and (2) reversal of provision for decommissioning costs. Shareholder Equity As of 31 December 2017, and 31 December 2018, the Group had shareholders
., BANGKAE, BANGKAE, BANGKOK, THAILAND. 10160 Tel: 02-455-2888 Fax: 02-455-2763 (“TRANSLATION”) TG 111/2561 May 14, 2018 Subject: Clarification of the Operating Result for the significant change Attention: The
., BANGKAE, BANGKAE, BANGKOK, THAILAND. 10160 Tel: 02-455-2888 Fax: 02-455-2763 (“TRANSLATION”) TG 154/2561 August 8, 2018 Subject: Clarification of the Operating Result for the significant change Attention
fully amortized cost of purchasing 34 36 40 Summary of Profit and Loss Statement 2016 2017 Change MB % MB % MB % Total Revenues 1,063.7 100.0% 1,356.3 100.0% 292.6 27.5% Cost of Services 377.9 35.5% 574.4
Company’s Performance Unit : Million Baht For the 3 months Change between QoQ Change between YoY For the 9 months Change between YoY Q3/18 Q2/18 Q3/17 Amount % Amount % Sep. 18 Sep. 17 Amount % Revenues from
management’ discussion and analysis for the 1st quarter in 2020, ended March 31st, 2020 as per herebelow : 3-Month Period Ended March 31st Change 2020 2019 % MB MB Sales Revenue 97.13 84.93 14.36 Total Revenue
estimated the new car sales for the year 2018 to end at 1.02 million units, a growth of 17%. 3 In the equity market, the average daily turnover (SET and mai) for the year 2018 increased 15.1% from Baht 50,114
0.00 0.00 Gain from change in a joint venture proportion 9.87 9.87 0.00 0.00 Other income 12.47 (1.28) 15.17 (1.25) Total income 1,168.60 (192.83) 1,181.02 (217.90) The Company wish to explain the main
results for the six-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech